Biogen
BIIB
1,097 hedge funds and large institutions have $51.9B invested in Biogen in 2018 Q2 according to their latest regulatory filings, with 82 funds opening new positions, 419 increasing their positions, 414 reducing their positions, and 79 closing their positions.
8% more funds holding in top 10
Funds holding in top 10: 26 → 28 (+2)
4% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 79
1% more repeat investments, than reductions
Existing positions increased: 419 | Existing positions reduced: 414
1% more capital invested
Capital invested by funds: $51.4B → $51.9B (+$457M)
0% less funds holding
Funds holding: 1,101 → 1,097 (-4)
4.01% less ownership
Funds ownership: 88.83% → 84.82% (-4%)
41% less call options, than puts
Call options by funds: $755M | Put options by funds: $1.28B
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$187M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$186M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$111M |
| 4 |
ClearBridge Investments
New York
|
+$95.8M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$85.3M |
Top Sellers
BIIB Hedge Fund Activity: Q2 2018 in Review
1,097 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q2 2018, worth a combined $51.9B — up 0.89% from $51.4B a quarter earlier.
Buyers outnumbered sellers: 82 funds opened new BIIB positions and 79 closed out — a net gain of 3 holders — while 419 added to existing stakes and 414 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $187M. The largest seller was T. Rowe Price Associates, cutting an estimated $576M.
- 1,097 institutional investors held Biogen (BIIB) as of Q2 2018, down from 1,101 in Q1 2018.
- Funds reported $51.9B of Biogen stock for Q2 2018, up 0.89% quarter-over-quarter.
- 82 funds opened new Biogen positions in Q2 2018 and 79 closed out, a net change of +3 holders.
- The largest Biogen buyer in Q2 2018 was Morgan Stanley, an estimated $187M added.
- The largest Biogen seller in Q2 2018 was T. Rowe Price Associates, an estimated $576M sold.
Based on aggregated 13F filings for Q2 2018.